Mindray Medical International Limited Given “Neutral” Rating at Zacks (MR)
Mindray Medical International Limited (NYSE:MR)‘s stock had its “neutral” rating reaffirmed by Zacks in a report issued on Tuesday, American Banking News reports. They currently have a $41.00 price target on the stock. Zacks‘ price objective points to a potential upside of 5.26% from the company’s current price.
A number of other analysts have also recently weighed in on MR. Analysts at Oppenheimer raised their price target on shares of Mindray Medical International Limited from $45.00 to $50.00 in a research note to investors on Wednesday, August 7th. Analysts at Credit Suisse downgraded shares of Mindray Medical International Limited from a “neutral” rating to an “underperform” rating in a research note to investors on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $40.93.
Mindray Medical International Limited (NYSE:MR) traded down 0.49% during mid-day trading on Tuesday, hitting $38.76. 474,747 shares of the company’s stock traded hands. Mindray Medical International Limited has a 52 week low of $28.65 and a 52 week high of $43.81. The stock’s 50-day moving average is $40.66 and its 200-day moving average is $39.84. The company has a market cap of $4.594 billion and a price-to-earnings ratio of 22.24.
Mindray Medical International Limited (NYSE:MR) last released its earnings data on Monday, August 5th. The company reported $0.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.47 by $0.09. The company had revenue of $307.20 million for the quarter, compared to the consensus estimate of $312.06 million. During the same quarter in the previous year, the company posted $0.50 earnings per share. The company’s revenue for the quarter was up 14.7% on a year-over-year basis.
Manufactures, develops and markets electro-medical equipment covering three fields of patient monitoring,clinical laboratory and ultrasonic diagnosis.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.